Compare EHTH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | ATAI |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1M | 1.4B |
| IPO Year | 2006 | 2021 |
| Metric | EHTH | ATAI |
|---|---|---|
| Price | $4.50 | $4.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.67 | ★ $14.00 |
| AVG Volume (30 Days) | 263.5K | ★ 3.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $542,951,000.00 | $3,018,000.00 |
| Revenue This Year | $4.92 | $943.83 |
| Revenue Next Year | $0.24 | N/A |
| P/E Ratio | $100.55 | ★ N/A |
| Revenue Growth | 16.79 | ★ 811.78 |
| 52 Week Low | $3.18 | $1.15 |
| 52 Week High | $11.36 | $6.75 |
| Indicator | EHTH | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 49.78 |
| Support Level | $3.64 | $4.25 |
| Resistance Level | $4.25 | $4.54 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | 0.07 | 0.10 |
| Stochastic Oscillator | 94.55 | 71.36 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.